255 related articles for article (PubMed ID: 14720033)
1. Beta2-agonist eutomers: a rational option for the treatment of asthma?
Boulton DW; Fawcett JP
Am J Respir Med; 2002; 1(5):305-11. PubMed ID: 14720033
[TBL] [Abstract][Full Text] [Related]
2. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
van der Woude HJ; Winter TH; Aalbers R
Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with levalbuterol.
Nelson HS
J Allergy Clin Immunol; 1999 Aug; 104(2 Pt 2):S77-84. PubMed ID: 10452792
[TBL] [Abstract][Full Text] [Related]
4. Long-Acting β2-Agonists in Asthma: Enantioselective Safety Studies are Needed.
Jacobson GA; Raidal S; Hostrup M; Calzetta L; Wood-Baker R; Farber MO; Page CP; Walters EH
Drug Saf; 2018 May; 41(5):441-449. PubMed ID: 29332144
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics of levosalbutamol: what are the clinical implications?
Boulton DW; Fawcett JP
Clin Pharmacokinet; 2001 Jan; 40(1):23-40. PubMed ID: 11236808
[TBL] [Abstract][Full Text] [Related]
6. Levalbuterol in the treatment of patients with asthma and chronic obstructive lung disease.
Dalonzo GE
J Am Osteopath Assoc; 2004 Jul; 104(7):288-93. PubMed ID: 15293593
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans.
Boulton DW; Fawcett JP
Clin Pharmacol Ther; 1997 Aug; 62(2):138-44. PubMed ID: 9284849
[TBL] [Abstract][Full Text] [Related]
8. Levalbuterol versus albuterol.
Ameredes BT; Calhoun WJ
Curr Allergy Asthma Rep; 2009 Sep; 9(5):401-9. PubMed ID: 19671384
[TBL] [Abstract][Full Text] [Related]
9. Single-isomer beta-agonists.
Handley DA
Pharmacotherapy; 2001 Mar; 21(3 Pt 2):21S-27S. PubMed ID: 11253864
[TBL] [Abstract][Full Text] [Related]
10. What is new with the beta2-agonists: issues in the management of asthma.
Kelly HW
Ann Pharmacother; 2005 May; 39(5):931-8. PubMed ID: 15811904
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients.
Palmqvist M; Ibsen T; Mellén A; Lötvall J
Am J Respir Crit Care Med; 1999 Jul; 160(1):244-9. PubMed ID: 10390407
[TBL] [Abstract][Full Text] [Related]
12. Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists.
van Schayck CP; Cloosterman SG; Bijl-Hofland ID; van den Hoogen H; Folgering HT; van Weel C
Respir Med; 2002 Mar; 96(3):155-62. PubMed ID: 11908511
[TBL] [Abstract][Full Text] [Related]
13. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
Frois C; Wu EQ; Ray S; Colice GL
Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
[TBL] [Abstract][Full Text] [Related]
14. Contrasting properties of albuterol stereoisomers.
Page CP; Morley J
J Allergy Clin Immunol; 1999 Aug; 104(2 Pt 2):S31-41. PubMed ID: 10452786
[TBL] [Abstract][Full Text] [Related]
15. Long-acting inhaled beta2-agonists in asthma therapy.
Moore RH; Khan A; Dickey BF
Chest; 1998 Apr; 113(4):1095-108. PubMed ID: 9554653
[TBL] [Abstract][Full Text] [Related]
16. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol.
Lipworth BJ; Aziz I
J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):88-92. PubMed ID: 9893190
[TBL] [Abstract][Full Text] [Related]
17. Beta-adrenoceptor responses of the airways: for better or worse?
Broadley KJ
Eur J Pharmacol; 2006 Mar; 533(1-3):15-27. PubMed ID: 16469310
[TBL] [Abstract][Full Text] [Related]
18. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group.
FitzGerald JM; Chapman KR; Della Cioppa G; Stubbing D; Fairbarn MS; Till MD; Brambilla R
J Allergy Clin Immunol; 1999 Mar; 103(3 Pt 1):427-35. PubMed ID: 10069876
[TBL] [Abstract][Full Text] [Related]
19. A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease.
Sovani MP; Whale CI; Tattersfield AE
Drug Saf; 2004; 27(10):689-715. PubMed ID: 15350154
[TBL] [Abstract][Full Text] [Related]
20. Preserved bronchial dilatation after salbutamol does not guarantee protection against bronchial hyperresponsiveness.
Sjöswärd KN; Josefsson M; Ahlner J; Schmekel B
Clin Physiol Funct Imaging; 2003 Jan; 23(1):14-20. PubMed ID: 12558609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
